PM360

SEPTEMBER 7, 2023

Therapeutic Talk: Doctors’ Reactions to Recent FDA Approvals in Respiratory, Gastro, Infectious Disease, and More The number of times HCPs mentioned new products approved by the FDA over the course of the month of May. It’s clear that there’s more to play out between Threads and its more established rival, X.”

Healthcare 52

Healthcare Healthcare FDA Doctors 52

Legacy MEDSearch

JANUARY 13, 2023

implantation of the HIT Reverse Hip Replacement System (Reverse HRS), under an FDA approved Investigational Device Exemption (IDE). Stephen Zabinski, MD, Director of the Division of Orthopaedic Surgery, Shore Medical Center in Somers Point, New Jersey, performed the first surgery using this exciting new technology on January 10, 2023.

FDA 98

FDA Safety Recruitment Patients 98

Legacy MEDSearch

APRIL 27, 2023

Food and Drug Administration (FDA) for the company’s SIRA RFA Electrosurgical Device (SIRA). Data supporting the breakthrough device designation will be presented at the 24th Annual Meeting for The American Society of Breast Surgeons in Boston, MA on April 26-30, 2023. For more information, visit Innoblative.com. Are you hiring?

FDA 52

FDA Food and Drug Administration Recruitment Medical 52

Legacy MEDSearch

AUGUST 21, 2023

Muratoglu invented the first crosslinked polyethylene, and the first of multiple generations of vitamin E, antioxidant polyethylene for leading orthopaedic companies. “We The first products for Activit-E will launch in the beginning of Q3 2023 for select U.S. Global expansion will begin in 2024. Headquartered in Gainesville, Fla.,

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Marketing 52

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 These actions occur at both the delivery site and other systemic locations, thereby promoting an immunogenic response that leads to cancer cell death.

Food and Drug Administration 88

Food and Drug Administration Transportation FDA Medical 88

PM360

SEPTEMBER 21, 2023

The recent wave of Alzheimer’s Disease (AD) drug approvals and promising pivotal trial data from various drug manufacturers has been celebrated by physicians, patients, caregivers, and advocacy groups across the U.S. 2 Yet the largest payer in the U.S. has seemingly taken a different point of view.

Manufacturing 99

Manufacturing FDA Recruitment Prospecting 99

Legacy MEDSearch

FEBRUARY 24, 2023

“During a routine physical exam, patients can now have access to advanced structural murmur detection and arrhythmia assessment by their primary care physician in seconds, making early intervention possible for millions of patients with silent cardiovascular disease. Older adults have a 1 in 10 chance of developing clinically significant VHD.

Physicians 98

Physicians Recruitment Patients FDA 98

Pharmaceutical Technology

MARCH 24, 2023

Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.

Competition 59

Competition Marketing FDA Physicians 59

Legacy MEDSearch

FEBRUARY 28, 2023

RADIANCE II is a randomized, sham-controlled US FDA IDE pivotal trial of the Paradise uRDN System in the treatment of patients with uncontrolled hypertension. The publication of these results in JAMA and JAMA Cardiology will bring the evidence of the performance of uRDN in the treatment of hypertension to a broad audience of physicians.”

Networking 98

Networking Medical Physicians Safety 98

pharmaphorum

SEPTEMBER 29, 2022

A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

European Pharmaceutical Review

JULY 13, 2023

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).

Medical 85

Medical Food and Drug Administration Pharmacology Medicine 85

European Pharmaceutical Review

DECEMBER 1, 2023

Dr Kane leads a team of subject matter experts at Thermo Fisher, covering drug products in both sterile injectable dosage and oral solid dosage forms. AK : Prefilled syringes are definitely more patient friendly, as patients can take them home and self-administer without needing a physician or a pharmacist.

Food and Drug Administration 83

Food and Drug Administration Manufacturing Pharma Patients 83

pharmaphorum

SEPTEMBER 16, 2022

The findings from the phase 3 trial of lebrikizumab noted that the most adverse side effects reported had been “nonserious and did not lead to treatment discontinuation”. The FDA granted lebrikizumab Fast Track designation in December 2019. However, side effects do happen. Dr Thyssen explained why these might have occurred.

Management 78

Management Side effects Patients Safety 78

Contrarian Sales Techniques

DECEMBER 14, 2022

This can lead to significant losses for large companies. In 2021, the demand for physician-administered drugs decreased due to the outbreak. J&J's outlook for the business remains positive, as it continues to expect its pharmaceutical business to grow at a high rate in 2023. in 2023. **The in 2022 and $3.66

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Sales Medicine 52

Legacy MEDSearch

DECEMBER 21, 2022

a groundbreaking respiratory support technology company, announced today that it has begun the manufacturing process for the ALICE CPB (Cardiopulmonary Bypass) device (the “ALICE device”) to undergo the Verification and Validation phase prior to its planned 2023 submission to the U.S. and Israel. Are you hiring?

Manufacturing 98

Manufacturing FDA Food and Drug Administration Medical 98

European Pharmaceutical Review

APRIL 10, 2024

Over the past decade, there has been an increase in discussions involving industry stakeholders, regulatory agencies, and physicians about developments in the emerging microbiome therapeutics industry. References US FDA approves Ferring’s Rebyota for Clostridioides difficile infection. 2023; 62:102111. cited 2024Feb].

Safety 83

Safety Patients Medical FDA 83

Legacy MEDSearch

DECEMBER 19, 2022

Knowing such a solution exists places both patients and physicians at ease, and will create opportunities in the future for patients who are experiencing these debilitating symptoms.” ” Sonorous NV received its initial seed funding in Q1 of 2022 and quickly developed their product to achieve first clinical use in less than 1 year.

Patients 98

Patients Recruitment Physicians Management 98

Pharmaceutical Technology

NOVEMBER 21, 2022

Meanwhile, the drug's closest TIL competitor, Iovance Biotherapeutics’ lifileucel, has begun a rolling BLA for advanced melanoma patients and could reach the market as early as Q3 2023. In April this year, the FDA provided new feedback on the potency assays, which Iovance indicated will be addressed in the latest BLA.

Manufacturing 59

Manufacturing Food and Drug Administration Medical science Patients 59

PM360

SEPTEMBER 7, 2023

Then, we must allow ourselves to be unconstrained by conventional practice and follow where that empathy leads to help meet their needs.” He kicked things over to the argenx labs in Ghent, Belgium where Peter Ulrichts, Scientific Lead, Neuromuscular Franchise, argenx, explained the science behind VYVGART.

Patients 105

Patients Pharma Education Doctors 105

Nixon Gwilt Law

JANUARY 16, 2024

Companies will also need to understand whether the FDA will consider their model to be software as a medical device (SaMD) that is subject to the FD&C Act. On a similar note, Carrie predicts that “point solution fatigue” will lead to roll-ups of digital health point solutions into more comprehensive, one-stop-shop platforms.

Healthcare 52

Healthcare Healthcare Management Insurance 52

Medgadget

FEBRUARY 17, 2023

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. are still done in an open fashion.

Physicians 80

Physicians Engineering Side effects Leads 80

Medgadget

MARCH 2, 2023

This leads to substantial damage to healthy tissues and too often results in poor outcomes. To make implantation of the Alpha DaRT sources easy and precise, the company developed dedicated applicators andadapted existing biopsy devices, that physicians are already acquainted with, to deliver the radioactive sources.

Manufacturing 83

Manufacturing Leads Patients Medicine 83

European Pharmaceutical Review

DECEMBER 27, 2023

5 Subsequently, transplant centres administering CAR T cells in various pharma-sponsored clinical trials had to establish multi-disciplinary teams, including not just haematologists and oncologists but also intensive-care physicians and nurses, nephrologists, neurologists, pharmacists and others. FDA; 2022 [cited 2023 Mar].

Manufacturing 83

Manufacturing Food and Drug Administration Patients Pharma 83

Clarivate

DECEMBER 14, 2023

The weight loss drug conundrum PBMs may rethink their coverage policies for GLP-1 receptor agonists after the November 2023 approval of Eli Lilly’s Zepbound whose active ingredient was already available as diabetes drug Mounjaro ® and which joins Novo Nordisk’s Wegovy ® among the latest class of FDA-approved options.

Marketing 52

Marketing Healthcare Healthcare Insurance 52